Regeneron Reports Phase 3 extension Data for Ipilimumab in IgA nephropathy

Regeneron today announced Phase 3 extension results for ipilimumab in patients with IgA nephropathy. The study demonstrated that ipilimumab demonstrates safety and tolerability compared to standard of care or placebo. These results provide important insights into the treatment of IgA nephropathy and support the continued development of ipilimumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.